Selective Role for Mek1 but not Mek2 in the Induction of Epidermal Neoplasia

被引:43
作者
Scholl, Florence A. [1 ,2 ]
Dumesic, Phillip A. [1 ,2 ]
Barragan, Deborah I. [1 ,2 ]
Harada, Kazutoshi [3 ]
Charron, Jean [4 ]
Khavari, Paul A. [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA
[2] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA
[3] Univ Yamanashi, Fac Med, Dept Dermatol, Chuo Ku, Yamanashi, Japan
[4] Univ Laval, Ctr Rech Cancerol, CHUQ, Hotel Dieu, Quebec City, PQ, Canada
关键词
RAS; ACTIVATION; MUTATION; KINASE; GROWTH;
D O I
10.1158/0008-5472.CAN-08-1963
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Ras/Raf/Mck/Erk mitogen-activated protein kinase pathway regulates fundamental processes in normal and malignant cells, including proliferation, differentiation, and cell survival. Mutations in this pathway have been associated with carcinogenesis and developmental disorders, making Mek1 and Mek2 prime therapeutic targets. In this study, we examined the requirement for Mek1 and Mek2 in skin neoplasia using the two-step 7,12-dimethylbenz(a)anthraacene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis model. Mice lacking epidermal Mek1 protein develop fewer papillomas than both wild-type and Mek2-null mice following DMBA/TPA treatment. Mek1 knockout mice had smaller papillomas, delayed tumor onset, and half the tumor burden of wild-type mice. Loss of one Mek1 allele, however, did not affect tumor development, indicating that one Mek1 allele is sufficient for normal papilloma formation. No difference in TPA-induced hyperproliferation, inflammation, or Erk activation was observed between wildtype, conditional Mek1 knockout, and Mek2-null mice, indicating that Mek1 findings were not due to a general failure of these processes. These data show that Mek1 is important for skin tumor development and that Mek2 cannot compensate for the loss of Mek1 function in this setting. [Cancer Res 2009;69(9):3772-8]
引用
收藏
页码:3772 / 3778
页数:7
相关论文
共 50 条
  • [21] Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059
    Lee, Ha-Rim
    Lee, Jeewoo
    Kim, Hyun-Jung
    PHARMACOLOGICAL RESEARCH, 2019, 149
  • [22] Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling
    Little, Annette S.
    Balmanno, Kathryn
    Sale, Matthew J.
    Smith, Paul D.
    Cook, Simon J.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 73 - 78
  • [23] Scaffolding mechanism of arrestin-2 in the cRaf/MEK1/ERK signaling cascade
    Qu, Changxiu
    Park, Ji Young
    Yun, Min Woo
    He, Qing-Tao
    Yang, Fan
    Kim, Kiae
    Ham, Donghee
    Li, Rui-Rui
    Iverson, T. M.
    Gurevich, Vsevolod V.
    Sun, Jin-Peng
    Chung, Ka Young
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (37)
  • [24] The Mek1 phosphorylation cascade plays a role in meiotic recombination of Schizosaccharomyces pombe
    Tougan, Takahiro
    Kasama, Takashi
    Ohtaka, Ayami
    Okuzaki, Daisuke
    Saito, Takamune T.
    Russell, Paul
    Nojima, Hiroshi
    CELL CYCLE, 2010, 9 (23) : 4688 - 4702
  • [25] Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 117 : 20 - 31
  • [26] MEK2 is a critical modulating mechanism to down-regulate GCIP stability and function in cancer cells
    Liang, Ruei-Yue
    Liu, Bang-Hung
    Huang, Chih-Jou
    Lin, Kuan-Ting
    Ko, Chih-Chung
    Huang, Lin-Lun
    Hsu, Bin
    Wu, Chun-Ying
    Chuang, Show-Mei
    FASEB JOURNAL, 2020, 34 (02) : 1958 - 1969
  • [27] The Use of a Chemical Biology in the Development of a Novel MEK1/2 Inhibitor
    Yoshida, Takayuki
    Yamaguchi, Takayuki
    Kawasaki, Hisashi
    Sakamoto, Shinji
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2016, 74 (05) : 462 - 468
  • [28] Potential roles of MEK1 on aging in Argopecten scallops
    Yuan, Ke
    Lu, Xia
    Ning, Junhao
    Chen, Min
    Wang, Quanchao
    Liu, Guilong
    Xu, Xin
    Xu, He
    Wang, Chunde
    FRONTIERS IN MARINE SCIENCE, 2022, 9
  • [29] Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
    Wang, Chao
    Wang, Han
    Zheng, Cangxin
    Liu, Zhenming
    Gao, Xiaozuo
    Xu, Fengrong
    Niu, Yan
    Zhang, Liangren
    Xu, Ping
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 218
  • [30] MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas
    Murugan, Avaniyapuram Kannan
    Dong, Jianli
    Xie, Jingwu
    Xing, Mingzhao
    CELL CYCLE, 2009, 8 (13) : 2122 - 2124